Glass House Brands (GLAS) Other Non-Current Liabilities (2020 - 2026)
Glass House Brands' (GLAS) quarterly Other Non-Current Liabilities came in at $36.0 million in Q1 2026, up 42.67% year-on-year from $25.3 million in Q1 2025, and up 7.85% on a QoQ basis from $33.4 million in Q4 2025.
Glass House Brands (GLAS) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Other Non-Current Liabilities data on file, last reported at $36.0 million in Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 42.67% year-over-year to $36.0 million in Q1 2026; TTM through Mar 2026 was $36.0 million, a 42.67% increase from a year earlier, with the FY2025 full-year figure at $33.4 million, up 60.11% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $36.0 million, up from $33.4 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for GLAS reached as high as $44.9 million in Q1 2022 and fell as low as -$31122.4 billion in Q3 2022.
- Historically, Other Non-Current Liabilities has averaged -$2067.4 billion across 5 years, with a median of $22.5 million in 2023.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 3808.88% in 2022 and fell as far as 79319112.67% in 2022.
- Year by year, Other Non-Current Liabilities stood at $14.7 million in 2022, then surged by 136.0% to $34.6 million in 2023, then plunged by 39.67% to $20.9 million in 2024, then soared by 60.11% to $33.4 million in 2025, then advanced by 7.85% to $36.0 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $36.0 million in Q1 2026, $33.4 million in Q4 2025, and $31.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.04 Mn |
| Dec 31, 2025 | 33.41 Mn |
| Sep 30, 2025 | 31.60 Mn |
| Jun 30, 2025 | 28.24 Mn |
| Mar 31, 2025 | 25.26 Mn |
| Dec 31, 2024 | 20.87 Mn |
| Sep 30, 2024 | 20.19 Mn |
| Jun 30, 2024 | 6.62 Mn |
| Mar 31, 2024 | 6.47 Mn |
| Dec 31, 2023 | 34.59 Mn |
| Sep 30, 2023 | -4,023.66 Bn |
| Jun 30, 2023 | 22.51 Mn |
| Mar 31, 2023 | 4.88 Mn |
| Dec 31, 2022 | 14.66 Mn |
| Sep 30, 2022 | -31,122.40 Bn |
| Jun 30, 2022 | 44.06 Mn |
| Mar 31, 2022 | 44.91 Mn |
| Dec 31, 2021 | 1.45 Mn |
| Sep 30, 2021 | 39.24 Mn |
| Mar 31, 2021 | 1.15 Mn |